Acorda Therapeutics (ACOR) Tops Q2 EPS by 22c
Tweet
Share
E-mail
Get Alerts ACOR Hot Sheet
Price: $0.66 --0%
Financial Fact:
Provision for income taxes: -3.02M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Provision for income taxes: -3.02M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of ($1.87), $0.22 better than the analyst estimate of ($2.09). Revenue for the quarter came in at $31.78 million versus the consensus estimate of $29.94 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- UBS says bull market has further to run
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
